Quanta Receives CE Mark for its Advanced Haemodialysis System SC+

Alcester, Warwickshire, UK, 6 January 2015: Quanta Fluid Solutions Ltd (“Quanta” or the “Company”), a pioneering developer of advanced haemodialysis systems, announces it has received CE mark for SC+, its portable, cartridge-based haemodialysis system.

SC+ is designed to bring flexibility to dialysis patients and physicians by supporting all treatment regimens, from nurse-assisted care and patient self-care in-centre to home haemodialysis.  SC+ is the only portable, compact haemodialysis system with the clinical efficacy and high flow rates of traditional in-centre machines.  The technology behind SC+ is based on an innovative and unique design that incorporates all fluid management activities onto a single-use disposable cartridge.

Quanta is also pleased to announce that it has raised additional funds expanding its recent investment round to a total of £29 million.  The round was led by new investor ALIAD, the venture capital investment vehicle of Air Liquide SA (Paris: AI), and included participation by additional new investors Seventure Partners and Kuwait Life Sciences Company, as well as existing investors Wellington Partners, Seroba Kernel, NBGI Ventures, b-to-v Partners and IMI plc (LSE: IMI).

John E. Milad, Chief Executive Officer of Quanta, said: “This is an exciting time for Quanta.  Obtaining CE mark for SC+ is a major milestone for us and is a testament to the ingenuity and engineering excellence of our team. SC+ is a revolutionary dialysis system based around a novel single-use disposable cartridge. Our system will provide meaningful benefits to patients and healthcare providers in terms of ease-of-use, flexibility and performance.  2014 was a transformational year for Quanta, and we are now strongly positioned to introduce SC+ for clinical use in 2015.”

Professor John Agar, a practicing clinical nephrologist, Clinical Conjoint Professor of Medicine at Deakin University School of Medicine at the Geelong Hospital, Barwon Health and Member of Quanta’s Medical Advisory Board, said:  “Quanta’s SC+ is the first real advance in dialysis system choice in a decade and a half. While small, light, and truly portable, it is still at its heart, a single pass dialysis system providing efficient and comparable dialysis to current technologies.  SC+ has the benefit of transferability from centre to home, and from home to centre, which gives valuable and flexible treatment options for physicians, patients and care givers. This is a truly game-changing technology.”



For more information, please contact:

Vicky La Touche-Price at Seroba Life Sciences
Tel: +3531 6334028


About Quanta
Quanta is developing advanced haemodialysis systems for use in the clinic and the home. The Company’s cartridge-based solution SC+ is the only portable, compact haemodialysis system with the clinical efficacy and high flow rates of traditional machines.  SC+ is designed to offer ease-of-use and flexibility, facilitating self-care and supporting dialysis patients across the entire continuum of care.

Quanta is privately owned and based in Alcester, UK.  The Company was founded in 2008 as a spin out from the FTSE 100 engineering company IMI plc, with funding provided by a group of leading venture capital investors specialised in healthcare: NBGI Ventures, Wellington Partners, Seroba Kernel and b-to-v Partners, and more recently ALIAD, Seventure Partners and Kuwait Life Sciences Company.

Quanta is dedicated to creating a paradigm shift in renal care and to improving the lives of dialysis patients.

For more information please visit: www.quantafs.com.


< back to home page